The pharmaceutical industry is making some bold constitutional arguments in its attempts to overturn a new law allowing Medicare to negotiate directly with drug makers on prices.
Listen here and subscribe to On The Merits on Apple Podcasts, Spotify, Google Podcasts, Megaphone, or Audible.
The industry says the law, part of the Biden administration’s Inflation Reduction Act, violates the Fifth, Eighth, and even First Amendment rights of companies like
On this episode of our weekly podcast, On The Merits, Celine Castronuovo and David Schultz look into why the drug makers are waging this uphill legal battle against Medicare negotiations and whether they’ll ultimately succeed.
Do you have feedback on this episode of On The Merits? Give us a call and leave a voicemail at 703-341-3690.
To contact the reporter on this story:
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.